Share
6,358 Posts.
lightbulb Created with Sketch. 204
clock Created with Sketch. 14/03/24
08:47
Share
Originally posted by Popp123:
↑
As long term shareholders it is easy to lose sight of the prize on offer. And the prize is huge. One company that is going gangbusters atm is Polynovo. They have a disruptive treatment for burns and wounds called Novosorb, only a one product company with a simple polyurethane mesh that mimics the dermis of the skin. This company is up 25% since reporting in late Feb. It's sales have exploded in the US and ROW. But it's main sales are in the US. It has a total addressable market of 500 million in the US. It sits on a PE greater than 1000 currently with 590 million listed shares. Now let's take Clinuvel who are looking at many indications for Scenesse but let's just take vitiligo on it's own. Vitiligo has the same total addressable market as Novosorb in the the US, roughly 500 million. But Clinuvel has the unique advantage of having only 49 million shares listed and a PE of only 20. Can you imagine the explosion in the PE and also share price when the vitiligo indication is approved and selling in the US. And by the way Polynovo was once heavily shorted too. Like Clinuvel. Lucky for them David Williams, their Chairman, took the shorts on by buying shares back with his own money. What a gun. Maybe a buyback in the short term for Clinuvel wouldn't be a bad idea either. Anyhow, my point to all of the above is that Clinuvel's share price may be in the dumps now but things can change very quickly with only one indication approved. So stay patient coz your reward will come. Good things take time.
Expand
Chairman buying shares, a good thing but not the same as a proper buyback, not that I am advocating a buy back or not.
(20min delay)